ADVM
Adverum Biotechnologies Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 11-08-2018 | 08-08-2018 | 05-09-2018 | 03-06-2018 | 11-08-2017 | 08-08-2017 | 05-09-2017 | |
|---|---|---|---|---|---|---|---|
| Actual EPS | -0.26 | -0.3 | -0.3 | -0.32 | -0.32 | -0.27 | -0.38 |
| Consensus EPS | -0.3 | -0.31 | -0.29 | -0.34 | -0.3 | -0.37 | -0.26 |
| Estimated EPS | -0.3 | -0.31 | -0.29 | -0.34 | -0.3 | -0.37 | -0.26 |
| Number of Estimates | 4 | 3 | 3 | 3 | 2 | 1 | 1 |
| EPS Surprise | $0.04 | $0.01 | -$0.01 | $0.02 | -$0.02 | $0.10 | -$0.12 |
Stats
Summary
Adverum Biotechnologies Inc is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye.
Market Cap: 291 Million
Primary Exchange: NASDAQ Global Market
Website: http://www.avalanchebiotech.com
Shares Outstanding: 45 Million
Float: 40.5 Million
Dividend: 0.0 (0.0%)
Beta: 3.583083
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 475 Thousand
Ethical Flags
Longest drawdown: 1069 trading days
From: 2015-01-07 To: 2019-02-20
Lowest Point:
Adverum Biotechnologies (ADVM) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-01-10 12:47:16:000
The following slide deck was published by Adverum Biotechnologies, Inc. in conjunction with this Read more … read more...
Adverum Biotechnologies (ADVM) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-01-10 12:47:16:000
The following slide deck was published by Adverum Biotechnologies, Inc. in conjunction with this Read more … read more...
Adverum Biotechnologies (ADVM) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-01-10 12:47:16:000
The following slide deck was published by Adverum Biotechnologies, Inc. in conjunction with this Read more … read more...
Adverum Biotechnologies provides 2019 outlook
via: SeekingAlpha at 2019-01-07 08:27:49:000
Adverum Biotechnologies (NASDAQ: ADVM ) provides an outlook for 2019. More news on: Adverum Biotechnologies, Inc., Healthcare stocks news, Read more … read more...
Adverum Biotechnologies provides 2019 outlook
via: SeekingAlpha at 2019-01-07 08:27:49:000
Adverum Biotechnologies (NASDAQ: ADVM ) provides an outlook for 2019. More news on: Adverum Biotechnologies, Inc., Healthcare stocks news, Read more … read more...
Adverum Biotechnologies provides 2019 outlook
via: SeekingAlpha at 2019-01-07 08:27:49:000
Adverum Biotechnologies (NASDAQ: ADVM ) provides an outlook for 2019. More news on: Adverum Biotechnologies, Inc., Healthcare stocks news, Read more … read more...
Homology Medicines up 4%
via: SeekingAlpha at 2018-12-10 13:08:53:000
Thinly traded gene therapy developer Homology Medicines ( FIXX +3.6% ) is up on below-average volume. Shares have rallied over 42% since touching $18.20 on November 21. More news on: Homology Medicines, MeiraGTx Holdings plc, Genprex, Inc, Healthcare stocks news, Stocks on th… read more...
Homology Medicines up 4%
via: SeekingAlpha at 2018-12-10 13:08:53:000
Thinly traded gene therapy developer Homology Medicines ( FIXX +3.6% ) is up on below-average volume. Shares have rallied over 42% since touching $18.20 on November 21. More news on: Homology Medicines, MeiraGTx Holdings plc, Genprex, Inc, Healthcare stocks news, Stocks on th… read more...
Adverum Biotechnologies misses by $0.05, beats on revenue
via: SeekingAlpha at 2018-11-08 16:51:57:000
Adverum Biotechnologies (NASDAQ: ADVM ): Q3 GAAP EPS of -$0.34 misses by $0.05 . More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Adverum Biotechnologies misses by $0.05, beats on revenue
via: SeekingAlpha at 2018-11-08 16:51:57:000
Adverum Biotechnologies (NASDAQ: ADVM ): Q3 GAAP EPS of -$0.34 misses by $0.05 . More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Adverum Biotechnologies misses by $0.05, beats on revenue
via: SeekingAlpha at 2018-11-08 16:51:57:000
Adverum Biotechnologies (NASDAQ: ADVM ): Q3 GAAP EPS of -$0.34 misses by $0.05 . More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Healthcare and Tech top list of midday movers (11/02/2018)
via: SeekingAlpha at 2018-11-02 12:47:27:000
More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more … read more...
Healthcare and Tech top list of midday movers (11/02/2018)
via: SeekingAlpha at 2018-11-02 12:47:27:000
More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more … read more...
Healthcare and Tech top list of midday movers (11/02/2018)
via: SeekingAlpha at 2018-11-02 12:47:27:000
More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more … read more...
Healthcare and Tech top list of midday movers (11/02/2018)
via: SeekingAlpha at 2018-11-02 12:47:27:000
More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more … read more...
Healthcare and Tech top list of midday movers (11/02/2018)
via: SeekingAlpha at 2018-11-02 12:47:27:000
More news on: Pacific Biosciences of California, Emerge Energy Services LP, VivoPower International PLC, Stocks on the move, , Read more … read more...
JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action
via: SeekingAlpha at 2018-11-02 07:59:00:000
Abiomed (NASDAQ: ABMD ) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket. More news on: ABIOMED, Inc., Emergent BioSolutions Inc., Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the mov… read more...
JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action
via: SeekingAlpha at 2018-11-02 07:59:00:000
Abiomed (NASDAQ: ABMD ) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket. More news on: ABIOMED, Inc., Emergent BioSolutions Inc., Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the mov… read more...
JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action
via: SeekingAlpha at 2018-11-02 07:59:00:000
Abiomed (NASDAQ: ABMD ) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket. More news on: ABIOMED, Inc., Emergent BioSolutions Inc., Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the mov… read more...
JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action
via: SeekingAlpha at 2018-11-02 07:59:00:000
Abiomed (NASDAQ: ABMD ) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket. More news on: ABIOMED, Inc., Emergent BioSolutions Inc., Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the mov… read more...
JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action
via: SeekingAlpha at 2018-11-02 07:59:00:000
Abiomed (NASDAQ: ABMD ) upgraded to Buy with a $450 (19% upside) price target at BTIG Research after yesterday's fiscal Q2 beat. Shares up a fraction premarket. More news on: ABIOMED, Inc., Emergent BioSolutions Inc., Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the mov… read more...
Adverum -29.7% as it ends therapy for A1AT deficiency
via: SeekingAlpha at 2018-11-01 18:23:03:000
Adverum (NASDAQ: ADVM ) has slid 29.7% after hours after a program update says it's going to end development of its gene therapy for A1AT deficiency . More news on: Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Adverum Bio's gene therapy ADVM-022 shows positive action in preclinical wet AMD study
via: SeekingAlpha at 2018-10-17 10:06:00:000
Results from a preclinical study evaluating Adverum Biotechnologies' ( ADVM -0.4% ) gene therapy ADVM-022 in a non-human primate model of wet age-related macular degeneration (wet AMD) showed an encouraging treatment effect. The data were presented at the ESGCT Congress in Switzerland. … read more...
Adverum Bio's gene therapy ADVM-022 shows positive action in preclinical wet AMD study
via: SeekingAlpha at 2018-10-17 10:06:00:000
Results from a preclinical study evaluating Adverum Biotechnologies' ( ADVM -0.4% ) gene therapy ADVM-022 in a non-human primate model of wet age-related macular degeneration (wet AMD) showed an encouraging treatment effect. The data were presented at the ESGCT Congress in Switzerland. … read more...
Adverum Bio's gene therapy ADVM-022 shows positive action in preclinical wet AMD study
via: SeekingAlpha at 2018-10-17 10:06:00:000
Results from a preclinical study evaluating Adverum Biotechnologies' ( ADVM -0.4% ) gene therapy ADVM-022 in a non-human primate model of wet age-related macular degeneration (wet AMD) showed an encouraging treatment effect. The data were presented at the ESGCT Congress in Switzerland. … read more...
Your Daily Pharma Scoop: Tocagen Ahead Of Schedule, Adverum Fast-Tracked, Molecular's New Deal
via: SeekingAlpha at 2018-09-25 14:33:59:000
Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space and also provide quick commentary on other imp… read more...
Your Daily Pharma Scoop: Tocagen Ahead Of Schedule, Adverum Fast-Tracked, Molecular's New Deal
via: SeekingAlpha at 2018-09-25 14:33:59:000
Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space and also provide quick commentary on other imp… read more...
Your Daily Pharma Scoop: Tocagen Ahead Of Schedule, Adverum Fast-Tracked, Molecular's New Deal
via: SeekingAlpha at 2018-09-25 14:33:59:000
Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space and also provide quick commentary on other imp… read more...
Adverum +11% as FDA gives fast-track to new gene therapy
via: SeekingAlpha at 2018-09-19 18:49:58:000
Adverum Biotechnologies (NASDAQ: ADVM ) has jumped 11.1% after hours following word a few minutes ago that it's gotten fast-track designation for its ADVM-022 gene therapy candidate. More news on: Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Adverum +11% as FDA gives fast-track to new gene therapy
via: SeekingAlpha at 2018-09-19 18:49:58:000
Adverum Biotechnologies (NASDAQ: ADVM ) has jumped 11.1% after hours following word a few minutes ago that it's gotten fast-track designation for its ADVM-022 gene therapy candidate. More news on: Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Adverum +11% as FDA gives fast-track to new gene therapy
via: SeekingAlpha at 2018-09-19 18:49:58:000
Adverum Biotechnologies (NASDAQ: ADVM ) has jumped 11.1% after hours following word a few minutes ago that it's gotten fast-track designation for its ADVM-022 gene therapy candidate. More news on: Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Gene therapy players under pressure
via: SeekingAlpha at 2018-09-05 10:58:30:000
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks … read more...
Gene therapy players under pressure
via: SeekingAlpha at 2018-09-05 10:58:30:000
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks … read more...
Gene therapy players under pressure
via: SeekingAlpha at 2018-09-05 10:58:30:000
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks … read more...
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
via: SeekingAlpha at 2018-09-01 05:42:38:000
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516… read more...
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
via: SeekingAlpha at 2018-09-01 05:42:38:000
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516… read more...
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
via: SeekingAlpha at 2018-09-01 05:42:38:000
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516… read more...
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
via: SeekingAlpha at 2018-09-01 05:42:38:000
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-30 08:26:01:000
Adverum Biotechnologies (NASDAQ: ADVM ) initiated with Buy rating and $11 (80% upside) price target at SunTrust. Shares up 2% premarket. More news on: Adverum Biotechnologies, Inc., Glaukos, Tocagen Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-30 08:26:01:000
Adverum Biotechnologies (NASDAQ: ADVM ) initiated with Buy rating and $11 (80% upside) price target at SunTrust. Shares up 2% premarket. More news on: Adverum Biotechnologies, Inc., Glaukos, Tocagen Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Adverum Biotechnologies announces IND active for ADVM-022 to treat wAMD
via: SeekingAlpha at 2018-08-30 07:49:49:000
Adverum Biotechnologies (NASDAQ: ADVM ) announces its Investigational New Drug (IND) application is active for the Phase 1, dose-escalation study of ADVM-022, a novel gene therapy candidate for the treatment of wet age-related macular degeneration (wAMD). More news on: Adverum Biotechnol… read more...
Adverum Biotechnologies announces IND active for ADVM-022 to treat wAMD
via: SeekingAlpha at 2018-08-30 07:49:49:000
Adverum Biotechnologies (NASDAQ: ADVM ) announces its Investigational New Drug (IND) application is active for the Phase 1, dose-escalation study of ADVM-022, a novel gene therapy candidate for the treatment of wet age-related macular degeneration (wAMD). More news on: Adverum Biotechnol… read more...
FDA OKs Shire's Takhzyro for HAE
via: SeekingAlpha at 2018-08-23 22:43:20:000
The FDA approves Shire plc's (NASDAQ: SHPG ) TAKHZYRO (lanadelumab-flyo) for the prevention of attacks of hereditary angioedema (HAE) in patients at least 12 years old. More news on: Shire PLC, Adverum Biotechnologies, Inc., BioCryst Pharmaceuticals, Inc., Healthcare stocks news, Rea… read more...
FDA OKs Shire's Takhzyro for HAE
via: SeekingAlpha at 2018-08-23 22:43:20:000
The FDA approves Shire plc's (NASDAQ: SHPG ) TAKHZYRO (lanadelumab-flyo) for the prevention of attacks of hereditary angioedema (HAE) in patients at least 12 years old. More news on: Shire PLC, Adverum Biotechnologies, Inc., BioCryst Pharmaceuticals, Inc., Healthcare stocks news, Rea… read more...
FDA OKs Shire's Takhzyro for HAE
via: SeekingAlpha at 2018-08-23 22:43:20:000
The FDA approves Shire plc's (NASDAQ: SHPG ) TAKHZYRO (lanadelumab-flyo) for the prevention of attacks of hereditary angioedema (HAE) in patients at least 12 years old. More news on: Shire PLC, Adverum Biotechnologies, Inc., BioCryst Pharmaceuticals, Inc., Healthcare stocks news, Rea… read more...
FDA OKs Shire's Takhzyro for HAE
via: SeekingAlpha at 2018-08-23 22:43:20:000
The FDA approves Shire plc's (NASDAQ: SHPG ) TAKHZYRO (lanadelumab-flyo) for the prevention of attacks of hereditary angioedema (HAE) in patients at least 12 years old. More news on: Shire PLC, Adverum Biotechnologies, Inc., BioCryst Pharmaceuticals, Inc., Healthcare stocks news, Rea… read more...
FDA OKs Shire's Takhzyro for HAE
via: SeekingAlpha at 2018-08-23 22:43:20:000
The FDA approves Shire plc's (NASDAQ: SHPG ) TAKHZYRO (lanadelumab-flyo) for the prevention of attacks of hereditary angioedema (HAE) in patients at least 12 years old. More news on: Shire PLC, Adverum Biotechnologies, Inc., BioCryst Pharmaceuticals, Inc., Healthcare stocks news, Rea… read more...
FDA and NIH to loosen oversight of gene therapy development
via: SeekingAlpha at 2018-08-16 09:47:09:000
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...
FDA and NIH to loosen oversight of gene therapy development
via: SeekingAlpha at 2018-08-16 09:47:09:000
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...
FDA and NIH to loosen oversight of gene therapy development
via: SeekingAlpha at 2018-08-16 09:47:09:000
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...
Adverum Biotechnologies reports Q2 results
via: SeekingAlpha at 2018-08-08 16:54:32:000
Adverum Biotechnologies (NASDAQ: ADVM ): Q2 EPS of -$0.30 More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Adverum Biotechnologies reports Q2 results
via: SeekingAlpha at 2018-08-08 16:54:32:000
Adverum Biotechnologies (NASDAQ: ADVM ): Q2 EPS of -$0.30 More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Adverum Biotechnologies reports Q2 results
via: SeekingAlpha at 2018-08-08 16:54:32:000
Adverum Biotechnologies (NASDAQ: ADVM ): Q2 EPS of -$0.30 More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Gene therapy players in the green
via: SeekingAlpha at 2018-06-20 14:27:32:000
Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta's ( SRPT +7.1% ) bullish news yesterday. More news on: Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...
Gene therapy players in the green
via: SeekingAlpha at 2018-06-20 14:27:32:000
Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta's ( SRPT +7.1% ) bullish news yesterday. More news on: Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...
A Review Of Adeno-Associated Virus Mediated Gene Therapies And A Closer Look At Adverum's ADV-043
via: SeekingAlpha at 2018-06-18 08:15:00:000
Gene Therapy In Context Few terms in medicine invoke more awe and fascination than Gene Therapy. Ever since the discovery of DNA and our understanding that within the basic genetic code lies the basis for so many different disease states, scientists have plotted to devise ways to f… read more...
A Review Of Adeno-Associated Virus Mediated Gene Therapies And A Closer Look At Adverum's ADV-043
via: SeekingAlpha at 2018-06-18 08:15:00:000
Gene Therapy In Context Few terms in medicine invoke more awe and fascination than Gene Therapy. Ever since the discovery of DNA and our understanding that within the basic genetic code lies the basis for so many different disease states, scientists have plotted to devise ways to f… read more...
CRISPR/Cas9 gene editors weigh on gene therapy stocks
via: SeekingAlpha at 2018-06-11 14:05:45:000
Most gene therapy stocks are in the red, led by the CRISPR/Cas9 players after two studies were published about the potential cancer risk related to edited cells. More news on: Fibrocell Science, Inc., Rocket Pharmaceuticals, Inc., Abeona Therapeutics Inc., Healthcare stocks news, Stocks on… read more...
CRISPR/Cas9 gene editors weigh on gene therapy stocks
via: SeekingAlpha at 2018-06-11 14:05:45:000
Most gene therapy stocks are in the red, led by the CRISPR/Cas9 players after two studies were published about the potential cancer risk related to edited cells. More news on: Fibrocell Science, Inc., Rocket Pharmaceuticals, Inc., Abeona Therapeutics Inc., Healthcare stocks news, Stocks on… read more...
CRISPR/Cas9 gene editors weigh on gene therapy stocks
via: SeekingAlpha at 2018-06-11 14:05:45:000
Most gene therapy stocks are in the red, led by the CRISPR/Cas9 players after two studies were published about the potential cancer risk related to edited cells. More news on: Fibrocell Science, Inc., Rocket Pharmaceuticals, Inc., Abeona Therapeutics Inc., Healthcare stocks news, Stocks on… read more...
Trump set to sign "right to try" bill; biotechs rally
via: SeekingAlpha at 2018-05-23 11:51:47:000
Many biotechs are in the green in early trade after the U.S. House of Representatives voted in favor of the Senate's version of "right to try" legislation yesterday. The bill, expected to be quickly signed into law by President Trump, will allow people with life-threatening illnesses to ob… read more...
Trump set to sign "right to try" bill; biotechs rally
via: SeekingAlpha at 2018-05-23 11:51:47:000
Many biotechs are in the green in early trade after the U.S. House of Representatives voted in favor of the Senate's version of "right to try" legislation yesterday. The bill, expected to be quickly signed into law by President Trump, will allow people with life-threatening illnesses to ob… read more...
Trump set to sign "right to try" bill; biotechs rally
via: SeekingAlpha at 2018-05-23 11:51:47:000
Many biotechs are in the green in early trade after the U.S. House of Representatives voted in favor of the Senate's version of "right to try" legislation yesterday. The bill, expected to be quickly signed into law by President Trump, will allow people with life-threatening illnesses to ob… read more...
Adverum: Assessing The Strong Prospects Of A Gene Therapy Innovator
via: SeekingAlpha at 2018-05-23 06:00:01:000
Back in 2017, Spark Therapeutics (NASDAQ: ONCE ) won the first FDA-approval for voretigene neparvovec-rzyl (Luxturna) - a one-time gene therapy for patients afflicted with biallelic RPE65 mutation-associated retinal dystrophy. The historic milestone foretold an incoming wave of stellar devel… read more...
Adverum: Assessing The Strong Prospects Of A Gene Therapy Innovator
via: SeekingAlpha at 2018-05-23 06:00:01:000
Back in 2017, Spark Therapeutics (NASDAQ: ONCE ) won the first FDA-approval for voretigene neparvovec-rzyl (Luxturna) - a one-time gene therapy for patients afflicted with biallelic RPE65 mutation-associated retinal dystrophy. The historic milestone foretold an incoming wave of stellar devel… read more...
Adverum: Assessing The Strong Prospects Of A Gene Therapy Innovator
via: SeekingAlpha at 2018-05-23 06:00:01:000
Back in 2017, Spark Therapeutics (NASDAQ: ONCE ) won the first FDA-approval for voretigene neparvovec-rzyl (Luxturna) - a one-time gene therapy for patients afflicted with biallelic RPE65 mutation-associated retinal dystrophy. The historic milestone foretold an incoming wave of stellar devel… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-18 08:57:57:000
Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Overweight rating and $60 (100% upside) price target at Piper Jaffray. More news on: Aimmune Therapeutics, Alpine Immune Sciences, Inc., Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
After Hours Gainers / Losers (05/11/2018)
via: SeekingAlpha at 2018-05-11 17:39:30:000
Top gainers: NEWT +3.8% . ANFI +2.8% . VSLR +2.3% . SNCR +2.1% . ZTO +2.0% . More news on: Newtek Business Services Inc., Amira Nature Foods, Vivint Solar, Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (05/11/2018)
via: SeekingAlpha at 2018-05-11 17:39:30:000
Top gainers: NEWT +3.8% . ANFI +2.8% . VSLR +2.3% . SNCR +2.1% . ZTO +2.0% . More news on: Newtek Business Services Inc., Amira Nature Foods, Vivint Solar, Stocks on the move, , News on ETFs, Read more … read more...
Adverum Biotechnologies misses by $0.01, misses on revenue
via: SeekingAlpha at 2018-05-09 16:40:26:000
Adverum Biotechnologies (NASDAQ: ADVM ): Q1 EPS of -$0.30 misses by $0.01 . More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Adverum Biotechnologies misses by $0.01, misses on revenue
via: SeekingAlpha at 2018-05-09 16:40:26:000
Adverum Biotechnologies (NASDAQ: ADVM ): Q1 EPS of -$0.30 misses by $0.01 . More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Midday Gainers / Losers (05/04/2018)
via: SeekingAlpha at 2018-05-04 13:15:32:000
Gainers: BSPM +33% . CVGI +35% . CRC +27% . EARS +26% . P +23% . KONA +23% . NGVC +22% . MED +22% . SHAK +22% . PTLA +21% . More news on: Biostar Pharmaceutic, Commercial Vehicle Group, Inc., California Resources Corporation, Stocks on the move, , … read more...
Midday Gainers / Losers (05/04/2018)
via: SeekingAlpha at 2018-05-04 13:15:32:000
Gainers: BSPM +33% . CVGI +35% . CRC +27% . EARS +26% . P +23% . KONA +23% . NGVC +22% . MED +22% . SHAK +22% . PTLA +21% . More news on: Biostar Pharmaceutic, Commercial Vehicle Group, Inc., California Resources Corporation, Stocks on the move, , … read more...
Adverum -9.5% amid departures of CEO, chief medical officer
via: SeekingAlpha at 2018-05-03 18:26:57:000
Adverum Biotechnologies (NASDAQ: ADVM ) is 9.5% lower after hours following word that CEO/President Amber Salzman is stepping down from those roles and the board. More news on: Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Adverum -9.5% amid departures of CEO, chief medical officer
via: SeekingAlpha at 2018-05-03 18:26:57:000
Adverum Biotechnologies (NASDAQ: ADVM ) is 9.5% lower after hours following word that CEO/President Amber Salzman is stepping down from those roles and the board. More news on: Adverum Biotechnologies, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Novartis takeout of AveXis stokes buying in gene therapy players
via: SeekingAlpha at 2018-04-09 07:19:12:000
Gene therapy developers bluebird bio (NASDAQ: BLUE ) and Audentes Therapeutics (NASDAQ: BOLD ) are up 8% and 10% premarket, respectively, both on light volume on the heels of Novartis' $8.7B bid for AveXis. More news on: bluebird bio, Inc., Audentes Therapeutics, In… read more...
Novartis takeout of AveXis stokes buying in gene therapy players
via: SeekingAlpha at 2018-04-09 07:19:12:000
Gene therapy developers bluebird bio (NASDAQ: BLUE ) and Audentes Therapeutics (NASDAQ: BOLD ) are up 8% and 10% premarket, respectively, both on light volume on the heels of Novartis' $8.7B bid for AveXis. More news on: bluebird bio, Inc., Audentes Therapeutics, In… read more...
Adverem Biotechnologies: Gene Therapy Company And Our New Buy
via: SeekingAlpha at 2018-04-08 00:19:36:000
We bought shares of Adverem Biotechnologies ( ADVM ). The stock has pulled back from its recent highs and is at an attractive entry point ahead of phase I/II data from an ongoing gene therapy trial in treating alpha-1 antitrypsin deficiency, A1ATD in the second half of this year. ADVM dat… read more...
Adverem Biotechnologies: Gene Therapy Company And Our New Buy
via: SeekingAlpha at 2018-04-08 00:19:36:000
We bought shares of Adverem Biotechnologies ( ADVM ). The stock has pulled back from its recent highs and is at an attractive entry point ahead of phase I/II data from an ongoing gene therapy trial in treating alpha-1 antitrypsin deficiency, A1ATD in the second half of this year. ADVM dat… read more...
After Hours Gainers / Losers (04/03/2018)
via: SeekingAlpha at 2018-04-03 17:36:52:000
Top gainers: EDAP +13.7% . HCC +5.9% . ADVM +3.1% . GFI +1.8% . PSTG +1.3% . More news on: EDAP TMS S.A., Warrior Met Coal, Adverum Biotechnologies, Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (04/03/2018)
via: SeekingAlpha at 2018-04-03 17:36:52:000
Top gainers: EDAP +13.7% . HCC +5.9% . ADVM +3.1% . GFI +1.8% . PSTG +1.3% . More news on: EDAP TMS S.A., Warrior Met Coal, Adverum Biotechnologies, Inc., Stocks on the move, , News on ETFs, Read more … read more...
After Hours Gainers / Losers (3/19/2018)
via: SeekingAlpha at 2018-03-19 17:41:28:000
Top gainers: ARNA +24.6% . ELGX +8.1% . HLIT +6.4% . AMTX +6.2% . MRNS +6.1% . More news on: Arena Pharmaceuticals, Inc., Endologix Inc, Harmonic Inc., Stocks on the move, , News on ETFs, Read more … read more...
Adverum: A Lot Done, A Lot More To Do
via: SeekingAlpha at 2018-03-15 01:43:01:000
This article was co-authored by Stepan Lavrouk, whose research and insights form the article's thesis. Stepan is an investment analyst with Almington Capital. 2018 has been a good year for shareholders of gene therapy small-cap Adverum Biotechnologies ( ADVM ). Since late December 2017, th… read more...
Adverum Biotechnologies beats by $0.01, misses on revenue
via: SeekingAlpha at 2018-03-06 23:28:48:000
Adverum Biotechnologies (NASDAQ: ADVM ): Q4 EPS of -$0.32 beats by $0.01 . Revenue of $0.46M (-6.1% Y/Y) misses by $0.04M . Press Release More news on: Adverum Biotechnologies, Inc., Earnings news and commentary, Healthcare stocks news, read more...
Biotech Forum Daily Digest For February 9th
via: SeekingAlpha at 2018-02-09 06:47:45:000
One cannot bring up boys to be eagles and then expect them to be sparrows . Edith Kermit Carow Roosevelt It was another ugly day in the market on Thursday. The Dow dropped over 1,000 points for the second time this week. The main biotech indices fell four to five percent,… read more...
Biotech Forum Daily Digest For February 9th
via: SeekingAlpha at 2018-02-09 06:47:45:000
One cannot bring up boys to be eagles and then expect them to be sparrows . Edith Kermit Carow Roosevelt It was another ugly day in the market on Thursday. The Dow dropped over 1,000 points for the second time this week. The main biotech indices fell four to five percent,… read more...
Biotech Forum Daily Digest For February 9th
via: SeekingAlpha at 2018-02-09 06:47:45:000
One cannot bring up boys to be eagles and then expect them to be sparrows . Edith Kermit Carow Roosevelt It was another ugly day in the market on Thursday. The Dow dropped over 1,000 points for the second time this week. The main biotech indices fell four to five percent,… read more...
Biotech Forum Daily Digest For February 9th
via: SeekingAlpha at 2018-02-09 06:47:45:000
One cannot bring up boys to be eagles and then expect them to be sparrows . Edith Kermit Carow Roosevelt It was another ugly day in the market on Thursday. The Dow dropped over 1,000 points for the second time this week. The main biotech indices fell four to five percent,… read more...
Biotech Forum Daily Digest For February 9th
via: SeekingAlpha at 2018-02-09 06:47:45:000
One cannot bring up boys to be eagles and then expect them to be sparrows . Edith Kermit Carow Roosevelt It was another ugly day in the market on Thursday. The Dow dropped over 1,000 points for the second time this week. The main biotech indices fell four to five percent,… read more...
Solid Biosciences slips
via: SeekingAlpha at 2018-01-30 12:10:06:000
Today's broad market selloff notwithstanding, recent IPO Solid Biosciences ( SLDB -11.4% ) slumps on lower-than-normal volume in apparent response to the departure of noted gene therapy researcher James Wilson from its Scientific Advisory Board. More news on: Solid Biosciences, Inc., A… read more...
Solid Biosciences slips
via: SeekingAlpha at 2018-01-30 12:10:06:000
Today's broad market selloff notwithstanding, recent IPO Solid Biosciences ( SLDB -11.4% ) slumps on lower-than-normal volume in apparent response to the departure of noted gene therapy researcher James Wilson from its Scientific Advisory Board. More news on: Solid Biosciences, Inc., A… read more...
Solid Biosciences slips
via: SeekingAlpha at 2018-01-30 12:10:06:000
Today's broad market selloff notwithstanding, recent IPO Solid Biosciences ( SLDB -11.4% ) slumps on lower-than-normal volume in apparent response to the departure of noted gene therapy researcher James Wilson from its Scientific Advisory Board. More news on: Solid Biosciences, Inc., A… read more...
Week 5 Breakout Forecast:  Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-01-28 01:31:19:000
Breakout Forecast Selections for Week 5: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...
Week 5 Breakout Forecast:  Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-01-28 01:31:19:000
Breakout Forecast Selections for Week 5: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...
Week 5 Breakout Forecast:  Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-01-28 01:31:19:000
Breakout Forecast Selections for Week 5: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...
Week 5 Breakout Forecast:  Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-01-28 01:31:19:000
Breakout Forecast Selections for Week 5: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
Adverum Bio adds to rally, up 8%
via: SeekingAlpha at 2018-01-25 13:33:20:000
Gene therapy outfit Adverum Biotechnologies ( ADVM +7.8% ) continues its northward march on more than a 5x surge in volume. Shares have more than doubled since mid-December. More news on: Adverum Biotechnologies, Inc., Read more … read more...
Adverum Bio adds to rally, up 8%
via: SeekingAlpha at 2018-01-25 13:33:20:000
Gene therapy outfit Adverum Biotechnologies ( ADVM +7.8% ) continues its northward march on more than a 5x surge in volume. Shares have more than doubled since mid-December. More news on: Adverum Biotechnologies, Inc., Read more … read more...
Adverum Bio adds to rally, up 8%
via: SeekingAlpha at 2018-01-25 13:33:20:000
Gene therapy outfit Adverum Biotechnologies ( ADVM +7.8% ) continues its northward march on more than a 5x surge in volume. Shares have more than doubled since mid-December. More news on: Adverum Biotechnologies, Inc., Read more … read more...
Week 4 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-01-21 02:53:39:000
Breakout Forecast Selections for Week 4: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...
Week 3 Breakout Forecast:  Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-01-13 12:44:46:000
Breakout Forecast Selections for Week 3: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. Detailed chart… read more...
Week 2 Breakout Forecast:  Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-01-06 12:58:33:000
Breakout Forecast Selections: For those that are new to this short-term selection method I would highly recommend that you review the end of year performance summary and the links to methodology articles about how these high volatility, typical low cap, breakout selections work. Basical… read more...
Healthcare Biotech Sector Breakout: How High Will It Go In 2018?
via: SeekingAlpha at 2018-01-04 20:27:34:000
From the Big Picture to Individual Stock Breakouts This analysis starts with a 14 year chart of the Dow Jones US Biotechnology Index shown below. As you can see in the chart, the last 3 years have been a classic "cup and handle" pattern consolidation period after about a 350% run up from 201… read more...
3 Things In Biotech You Should Learn Today: January 2, 2018
via: SeekingAlpha at 2018-01-02 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Mylan expands its biosimilar approvals around the world Company : Mylan (MYL) Therapy :… read more...
2018 Week 1 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2017-12-31 03:35:11:000
Breakout Forecast Selections: For those that are new to this short-term selection method I would highly recommend that you review the end of year performance summary and the links to my methodology articles about how these high volatility, typical low cap, breakout selections work. Basi… read more...
Adverum: Why This ~$3.50 Biotech 'Busted IPO' Gets Our 'Thumbs Up'
via: SeekingAlpha at 2017-12-29 07:59:57:000
There are no shortcuts to any place worth going . Beverly Sills I have gotten at least three inquiries about a small $3.50 biotech 'Busted IPO' this week. Given this, I am going to make an exclusive 'deep dive' we did on this intriguing small cap concern for The Busted IP… read more...
Your Daily Pharma Scoop: Synergy's New CEO, AbbVie Data, TiGenix Changes
via: SeekingAlpha at 2017-12-21 02:41:58:000
Content Analysis of coverage: SGYP Stocks in the news: ABBV, TIG, EGLT Analyst Ratings Insider Sales Insider Purchases Secondary Offerings Earnings Report Earnings Calendar Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|